Treatment of Exudative (Wet) Age-Related Macular Degeneration (AMD): The Promise of Meeting the Needs

Sunir Garg, MD

May 02, 2022

In reflecting upon an array of unmet needs regarding exudative (wet) age-related macular degeneration (AMD), Sunir Garg, MD, identifies easing the treatment burden of the disease as a short-term goal. Dr Garg then details the often onerous practicalities involved in maintaining regular and consistent therapeutic schedules within a largely older patient population.

Dr Garg then turns to recent pharmacologic innovations, such as anti-VEGF combined with ANG-2, implantable reservoirs, and gene therapy, that together present the promise of easing the treatment burden by cutting down on the need for injections and office visits.

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: Treatment of Exudative (Wet) Age-Related Macular Degeneration (AMD): The Promise of Meeting the Needs - Medscape - May 02, 2022.

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.